Case | Sex | Species | MIC of CLA (μg/mL) | Radiological pattern | Prior Treatment | Total treatment duration before AMK therapy (months) | Drugs at AMK initiation | Duration of AMK therapy (months) | Sputum conversion post-therapy | Radiological findings poet-therapy |
---|---|---|---|---|---|---|---|---|---|---|
#1 | M | M.avium | 0.25 | FC | CLA, EMB | 16 | CLA, EMB | 13 | + | Improvement |
#2 | F | M.avium | 0.5 | NB + FC | CLA, RIP, EMB | 4 | CLA, RIP, EMB | 7 | − | No change |
#3 | M | M.avium | >32 | NB | CLA, RIP, EMB | 52 | RIP, EMB, STFX | 6 | − | Worsening |
#4 | F | M.avium | 0.5 | NB | CLA, RIP, EMB | 124 | CLA, RIP, EMB | 5 | + | No change |
#5 | F | M.intracellulare | ≦0.03 | NB + FC | CLA, EMB | 9 | CLA, EMB | 20 | − | Worsening |
#6 | M | M.avium | 0.5 | NB | CLA, RIP, STFX, AMK div | 110 | CLA, RIP, STFX | 1a | Unevaluable | Unevaluable |
#7 | F | M.avium | >32 | NB + FC | RIP, STFX | 16 | RIP, STFX | < 1a | Unevaluable | Unevaluable |
#8 | F | M.avium | 2 | NB | CLA, RIP, EMB | 43 | CLA, RIP, EMB | 36b | − | No change |
#9 | F | M.avium | >32 | NB | RFB, MFLX | 221 | RFB, MFLX | 6 | − | Worsening |
#10 | F | M.avium | 0.5 | NB | CLA, RIP, EMB, STFX | 86 | CLA, RIP, EMB, STFX | 6, 7c | − | No change |
#11 | F | M.abscessus | − | NB | EMB, STFX | 29 | EMB, STFX | 24 | + | Improvement |
#12 | F | M.avium | >32 | NB + FC | CLA, EMB | 99 | CLA, EMB | 7, 9c | + | Worsening |
#13 | F | M.avium | 0.5 | NB | CLA, RIP, STFX | 72 | CLA, RIP, STFX | 6 | − | No change |
#14 | F | M.avium | >32 | NB + FC | RIP, EMB, STFX | 145 | RIP, EMB, STFX | 6 | + | Unchanged |
#15 | F | M.avium | >32 | NB | RIP, EMB, STFX | 81 | RIP, EMB, STFX | 13 | + | Improvement |
#16 | F | M.avium | 4 | NB + FC | CLA, RIP, EMB | 67 | CLA, RIP, EMB | 24 | + | Improvement |
#17 | F | M.abscessus | − | NB + FC | CLA, STFX, DOXY | 31 | STFX, DOXY, DRPM | 3a | Unevaluable | Unevaluable |
#18 | F | M.avium | >32 | NB | EMB, STFX | 55 | EMB, STFX | 6, <1c | − | No change |
#19 | F | M.avium | 4 | NB + FC | CLA, RIP, EMB | 112 | CLA, RIP, EMB | 7 | − | No change |
#20 | F | M.avium | 0.125 | NB + FC | CLA, RIP, EMB | 13 | CLA, RIP, EMB | 12 | + | Improvement |
#21 | F | M.abscessus | − | NB + FC | CLA, RIP, EMB | 25 | CLA, DOXY, DRPM | 12 | + | Improvement |
#22 | M | M.avium | 0.125 | NB | CLA, RIP, EMB, STFX | 83 | CLA, RIP, EMB, STFX | 10 | − | Worsening |
#23 | F | M.avium | >32 | NB | CLA, RIP, EMB | 131 | RIP, EMB | 6 | − | No change |
#24 | F | M.avium | >32 | NB + FC | RIP, EMB, STFX | 106 | RIP, EMB, STFX | 7, 6c | − | No change |
#25 | F | M.avium | 0.25 | NB | CLA, RIP, EMB | 46 | CLA, RIP, EMB | 9 | + | Improvement |
#26 | F | M.avium | 0.125 | NB + FC | CLA, RIP, EMB | 44 | CLA, RIP, EMB | 6 | − | No change |